280 related articles for article (PubMed ID: 33648461)
21. Altered expression of renin-angiotensin system receptors throughout colorectal adenoma-adenocarcinoma sequence.
Beitia M; Solano-Iturri JD; Errarte P; Sanz B; Perez I; Etxezarraga MC; Loizate A; Asumendi A; Larrinaga G
Int J Med Sci; 2019; 16(6):813-821. PubMed ID: 31337954
[No Abstract] [Full Text] [Related]
22. MRTFB suppresses colorectal cancer development through regulating SPDL1 and MCAM.
Kodama T; Marian TA; Lee H; Kodama M; Li J; Parmacek MS; Jenkins NA; Copeland NG; Wei Z
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23625-23635. PubMed ID: 31690663
[TBL] [Abstract][Full Text] [Related]
23. Decreased expression of SCUBE2 is associated with progression and prognosis in colorectal cancer.
Song Q; Li C; Feng X; Yu A; Tang H; Peng Z; Wang X
Oncol Rep; 2015 Apr; 33(4):1956-64. PubMed ID: 25672935
[TBL] [Abstract][Full Text] [Related]
24. KRAS mutation and abnormal expression of Cripto-1 as two potential candidate biomarkers for detection of colorectal cancer development.
Igder S; Mohammadiasl J; Azadpour S; Mansouri E; Ashktorab H; Mokarram P
J Cell Biochem; 2020 Apr; 121(4):2901-2908. PubMed ID: 31692030
[TBL] [Abstract][Full Text] [Related]
25. Analysis of select members of the E26 (ETS) transcription factors family in colorectal cancer.
Deves C; Renck D; Garicochea B; da Silva VD; Giulianni Lopes T; Fillman H; Fillman L; Lunardini S; Basso LA; Santos DS; Batista EL
Virchows Arch; 2011 Apr; 458(4):421-30. PubMed ID: 21318373
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
27. The roles of JK-1 (FAM134B) expressions in colorectal cancer.
Kasem K; Gopalan V; Salajegheh A; Lu CT; Smith RA; Lam AK
Exp Cell Res; 2014 Aug; 326(1):166-73. PubMed ID: 24973512
[TBL] [Abstract][Full Text] [Related]
28. Aberrant expression of m
Kuai D; Zhu S; Shi H; Yang R; Liu T; Liu H; Min L; Zhang S
Life Sci; 2021 May; 273():119258. PubMed ID: 33636176
[TBL] [Abstract][Full Text] [Related]
29. The clinicopathological significance of REIC expression in colorectal carcinomas.
Wang W; Zhu W; Xu XY; Nie XC; Yang X; Xing YN; Yu M; Liu YP; Takano Y; Zheng HC
Histol Histopathol; 2012 Jun; 27(6):735-43. PubMed ID: 22473694
[TBL] [Abstract][Full Text] [Related]
30. Over-expression of AURKA, SKA3 and DSN1 contributes to colorectal adenoma to carcinoma progression.
Chuang TP; Wang JY; Jao SW; Wu CC; Chen JH; Hsiao KH; Lin CY; Chen SH; Su SY; Chen YJ; Chen YT; Wu DC; Li LH
Oncotarget; 2016 Jul; 7(29):45803-45818. PubMed ID: 27329586
[TBL] [Abstract][Full Text] [Related]
31. Expression of hippo pathway in colorectal cancer.
Liang K; Zhou G; Zhang Q; Li J; Zhang C
Saudi J Gastroenterol; 2014; 20(3):188-94. PubMed ID: 24976283
[TBL] [Abstract][Full Text] [Related]
32. A gene expression and pre-mRNA splicing signature that marks the adenoma-adenocarcinoma progression in colorectal cancer.
Pesson M; Volant A; Uguen A; Trillet K; De La Grange P; Aubry M; Daoulas M; Robaszkiewicz M; Le Gac G; Morel A; Simon B; Corcos L
PLoS One; 2014; 9(2):e87761. PubMed ID: 24516561
[TBL] [Abstract][Full Text] [Related]
33. SPDEF Induces Quiescence of Colorectal Cancer Cells by Changing the Transcriptional Targets of β-catenin.
Lo YH; Noah TK; Chen MS; Zou W; Borras E; Vilar E; Shroyer NF
Gastroenterology; 2017 Jul; 153(1):205-218.e8. PubMed ID: 28390865
[TBL] [Abstract][Full Text] [Related]
34. Genetic and epigenetic aberrations occurring in colorectal tumors associated with serrated pathway.
Sakai E; Fukuyo M; Ohata K; Matsusaka K; Doi N; Mano Y; Takane K; Abe H; Yagi K; Matsuhashi N; Fukushima J; Fukayama M; Akagi K; Aburatani H; Nakajima A; Kaneda A
Int J Cancer; 2016 Apr; 138(7):1634-44. PubMed ID: 26510091
[TBL] [Abstract][Full Text] [Related]
35. A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics.
Farshidfar F; Weljie AM; Kopciuk KA; Hilsden R; McGregor SE; Buie WD; MacLean A; Vogel HJ; Bathe OF
Br J Cancer; 2016 Sep; 115(7):848-57. PubMed ID: 27560555
[TBL] [Abstract][Full Text] [Related]
36. Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression.
Ibrahim AE; Arends MJ; Silva AL; Wyllie AH; Greger L; Ito Y; Vowler SL; Huang TH; Tavaré S; Murrell A; Brenton JD
Gut; 2011 Apr; 60(4):499-508. PubMed ID: 21068132
[TBL] [Abstract][Full Text] [Related]
37. OVOL2 attenuates the expression of MAP3K8 to suppress epithelial mesenchymal transition in colorectal cancer.
Xia L; Gao J; Ma K; Lin H; Chen Y; Luo Q; Lian J
Pathol Res Pract; 2021 Aug; 224():153493. PubMed ID: 34098198
[TBL] [Abstract][Full Text] [Related]
38. High TrkB expression levels are associated with poor prognosis and EMT induction in colorectal cancer cells.
Fujikawa H; Tanaka K; Toiyama Y; Saigusa S; Inoue Y; Uchida K; Kusunoki M
J Gastroenterol; 2012 Jul; 47(7):775-84. PubMed ID: 22361863
[TBL] [Abstract][Full Text] [Related]
39. TDO2 knockdown inhibits colorectal cancer progression via TDO2-KYNU-AhR pathway.
Zhao L; Wang B; Yang C; Lin Y; Zhang Z; Wang S; Ye Y; Shen Z
Gene; 2021 Aug; 792():145736. PubMed ID: 34051337
[TBL] [Abstract][Full Text] [Related]
40. Clinical impacts of mammalian target of rapamycin expression in human colorectal cancers.
Alqurashi N; Gopalan V; Smith RA; Lam AK
Hum Pathol; 2013 Oct; 44(10):2089-96. PubMed ID: 23773481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
